Market Overview

UPDATE: Stifel Nicolaus Initiates Abbott Laboratories at Buy Post Spin

Share:
Related ABT
All The Markets Trump Moved During His Speech Today
The Fentanyl Abuse Epidemic
Watch Point Trust Co Buys Comcast Corp, Newell Brands Inc, Novartis AG, Sells Abbott ... (GuruFocus)

Stifel Nicolaus initiated Abbott Laboratories (NYSE: ABT) with a Buy rating and a $40.00 price target.

Stifel Nicolaus commented, "Post-spin, we believe Abbott is now a balanced, diversified medical products company with an attractive, long-term outlook for mid-to-upper single-digit sales growth and low double-digit EPS growth. Although ABT currently trades at a premium to its peers, we see potential for further EPS upside over time, driven by an intensified focus on growth and margin enhancing initiatives. Using a sum-of-the-parts valuation framework, we arrive at a $40 target price."

Abbott Laboratories closed at $34.46 on Thursday.

Latest Ratings for ABT

DateFirmActionFromTo
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!